The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SGHT | -3.7% | N/A | N/A | -85% |
| S&P | +14.5% | +93.32% | +14.09% | +54% |
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2010 and is headquartered in Menlo Park, CA.
The company is a newer player in the medical devices space.
The company recently became publicly traded.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $19.56M | -8.5% |
| Gross Profit | $16.59M | -9.6% |
| Gross Margin | 84.78% | -1.1% |
| Market Cap | $213.53M | -35.7% |
| Market Cap / Employee | $0.99M | 0.0% |
| Employees | 216 | 0.9% |
| Net Income | -$11.94M | 3.1% |
| EBITDA | -$11.54M | 8.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $101.50M | -14.1% |
| Accounts Receivable | $9.61M | -51.7% |
| Inventory | 6.2 | -8.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $40.00M | 15.9% |
| Short Term Debt | $0.57M | 11.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -36.08% | -4.8% |
| Return On Invested Capital | -40.44% | 14.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.75M | 20.8% |
| Operating Free Cash Flow | -$7.54M | 22.3% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.34 | 1.93 | 1.40 | 2.73 | -9.71% |
| Price to Sales | 3.99 | 2.32 | 1.58 | 2.80 | -33.10% |
| Price to Tangible Book Value | 3.34 | 1.93 | 1.40 | 2.73 | -9.71% |
| Enterprise Value to EBITDA | -21.01 | -8.93 | -4.00 | -13.26 | -33.33% |
| Return on Equity | -45.4% | -49.6% | -52.9% | -57.1% | 29.75% |
| Total Debt | $35.29M | $40.36M | $40.46M | $40.57M | 15.83% |
SGHT earnings call for the period ending June 30, 2022.
SGHT earnings call for the period ending March 31, 2022.
SGHT earnings call for the period ending December 31, 2021.
SGHT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
